Research and progress in clinical trials of anti-vascular endothelial growth factor drugs in the treatment of diabetic macular edema
10.3760/cma.j.cn511434-20210524-00268
- VernacularTitle:抗血管内皮生长因子药物治疗糖尿病黄斑水肿临床试验的研究与进展
- Author:
Yi GONG
1
;
Yan SHAO
;
Xiaorong LI
Author Information
1. 天津医科大学眼科医院 眼视光学院 眼科研究所 国家眼耳鼻喉疾病临床医学研究中心天津市分中心 天津市视网膜功能与疾病重点实验室，天津 300384
- Keywords:
Diabetic retinopathy;
Macular edema;
Angiogenesis iInhibitors;
Clinical trial;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2022;38(1):66-71
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic macular edema (DME) is one of the main reasons causing blindness in patients with diabetic retinopathy. In recent years, with the recognition of the pathogenic role of vascular endothelial growth factor (VEGF) in DME, many clinical trials of intravitreal injection of anti-VEGF drugs have been carried out at home and abroad, proving that it has significant effects in improving visual acuity and reducing macular edema, and has become the first-line treatment of DME. However, there are still many challenges in routine clinical application of anti-VEGF drugs, such as frequent injections, insensitivity to treatment, and it is unclear whether repeated injections will cause damage to retina. The pathophysiological process of DME is very complicated, in addition to VEGF, there are many inflammatory factors and growth factors involved. Clinical trials of long-acting anti-VEGF agents, drugs of other targets and gene therapy are also being carried out. It is believed that with the in-depth research and progress of clinical trials, the gradual application of anti-VEGF drugs, other drugs and therapy in clinical practice are just around the corner, which is expected to provide more convenient and effective treatments for DME patients in the future.
